UPCOMING SESSIONS in ET
Thu, Jul 30, 2026
5:00 – 6:00 AM Bangkok
The role of upfront autologous SCT for primary AL amyloidosis Tibor Kovacsovics Click Here To Register
UPCOMING SESSIONS in ET
Thu, Jul 30, 2026 · 5:00 – 6:00 AM Bangkok
The role of upfront autologous SCT for primary AL amyloidosis
Tibor Kovacsovics
Click Here To Register
View all sessions

Alnylam Rises as Investors Weigh Pipeline Momentum, Earnings Setup, and ATTR-CM Positioning

Source
Quiverquant

Alnylam Pharmaceuticals (ALNY) is up 3.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a mix of company-specific momentum and sector positioning rather than one single headline. Investors may be reacting to Alnylam’s recent neuroscience update, the scheduled July 30, 2026 second-quarter earnings report, and the company’s strengthened standing in ATTR-CM after a rival late-stage study failed earlier this month.